Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling

@article{Rommelfanger2012DynamicsOM,
  title={Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling},
  author={Diana M Rommelfanger and Chetan Offord and Jayashree Dev and Zeljko Bajzer and Richard Geoffrey Vile and David Dingli},
  journal={Gene Therapy},
  year={2012},
  volume={19},
  pages={543-549}
}
Tumor selective, replication competent viruses are being tested for cancer gene therapy. This approach introduces a new therapeutic paradigm due to potential replication of the therapeutic agent and induction of a tumor-specific immune response. However, the experimental outcomes are quite variable, even when studies utilize highly inbred strains of mice and the same cell line and virus. Recognizing that virotherapy is an exercise in population dynamics, we utilize mathematical modeling to… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Modeling oncolytic virotherapy: is complete tumor-tropism too much of a good thing?

  • Journal of theoretical biology
  • 2014
VIEW 7 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 60 REFERENCES

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2011

Interference of CD 40 Lmediated tumor immunotherapy by oncolytic vesicular stomatitis virus

F Galivo, RM Diaz, +3 authors G Barber
  • Hum Gene Ther
  • 2010

Interference of CD 40 Lmediated tumor immunotherapy by oncolytic vesicular stomatitis virus

F Galivo, RM Diaz, +3 authors G Barber
  • Hum Gene Ther
  • 2010

Optimization of virotherapy for cancer

NL Komarova, D Wodarz
  • Bull Math Biol
  • 2010